Search Results - "Al-Roughani, Raed"

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines.

    Authors: Yamout, Bassem Gouider, Riadh Al-Roughani, Raed et al.

    Source: CNS Drugs. Mar2026, Vol. 40 Issue 3, p283-303. 21p.

    Subjects: Neuromyelitis optica, Therapeutics, Autoimmune diseases, Diagnosis, Aquaporins, Immunotherapy

    Geographic Terms: Middle East, North Africa

    Save to List
  2. 2

    Safety and effectiveness of disease-modifying therapies after switching from natalizumab.

    Authors: Zeineddine, Maya Al-Roughani, Raed Farouk Ahmed, Samar et al.

    Source: Multiple Sclerosis Journal. Jul2024, Vol. 30 Issue 8, p1026-1035. 10p.

    HTML Full Text PDF Full Text
    Save to List
  3. 3

    The Association of Vitamin D Receptor Polymorphisms with Multiple Sclerosis in a Case-Control Study from Kuwait.

    Authors: Al-Temaimi, Rabeah Abbas Al-Enezi, Anwar Al-Serri, Ahmad et al.

    Source: PLoS ONE. 11/5/2015, Vol. 10 Issue 10, p1-10. 10p.

    PDF Full Text
    Save to List
  4. 4

    The real-world effectiveness and safety of off-label rituximab in a large cohort of Middle Eastern multiple sclerosis patients.

    Authors: Ismail G Zeineddine M Al-Roughani R et al.

    Source: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics [Neurotherapeutics] 2026 Mar; Vol. 23 (2), pp. e00861. Date of Electronic Publication: 2026 Mar 12.

    Publication Type: Journal Article; Observational Study; Multicenter Study

    Journal Info: Publisher: Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics Country of Publication: United States NLM ID: 101290381 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-7479 (Electronic) Linking ISSN: 18787479 NLM ISO Abbreviation: Neurotherapeutics Subsets: MEDLINE

    Save to List
  5. 5

    Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based study.

    Authors: Zeineddine M Al-Hajje A Salameh P et al.

    Source: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2024 Oct; Vol. 90, pp. 105790. Date of Electronic Publication: 2024 Jul 28.

    Publication Type: Journal Article; Multicenter Study

    Journal Info: Publisher: Elsevier B. V Country of Publication: Netherlands NLM ID: 101580247 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-0356 (Electronic) Linking ISSN: 22110348 NLM ISO Abbreviation: Mult Scler Relat Disord Subsets: MEDLINE

    Save to List
  6. 6

    Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study.

    Authors: Al-Roughani R Zakaria M Cupler EJ et al.

    Source: Frontiers in neurology [Front Neurol] 2023 Nov 28; Vol. 14, pp. 1257455. Date of Electronic Publication: 2023 Nov 28 (Print Publication: 2023).

    Publication Type: Journal Article

    Journal Info: Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101546899 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2295 (Print) Linking ISSN: 16642295 NLM ISO Abbreviation: Front Neurol Subsets: PubMed not MEDLINE

    Save to List

Search Tools: